Actively Recruiting
Global Phase 3 Study Comparing Firmonertinib With Investigator-Selected EGFR Inhibitors for First-Line Treatment of Advanced or Metastatic NSCLC with EGFR PACC Mutations
Led by ArriVent BioPharma, Inc. · Updated on 2026-11-02
480
Participants Needed
141
Research Sites
95 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a global, Phase 3, randomized, open-label study to evaluate the effectiveness and safety of firmonertinib compared to the investigators choice of osimertinib or afatinib as first-line treatments. The study focuses on adults with locally advanced or metastatic non-small-cell lung cancer NSCLC who have specific uncommon EGFR PACC mutations and have not received prior therapy for advanced disease. Participants will be randomly assigned in a 11 ratio to receive either 240 mg of firmonertinib daily or the investigators choice of 80 mg osimertinib or 40 mg afatinib daily. The treatments are oral tablets taken once a day. The study will continue until disease progression or death, with assessments lasting up to approximately 4 years. During the study, participants will undergo regular evaluations including tumor progression and response assessments by blinded independent central review. Researchers will monitor safety through adverse event reporting and laboratory tests over approximately 5 years. The main outcomes measured are progression-free survival and overall response rate, with additional assessments of overall survival, duration of response, and treatment tolerability. Participation may last up to about 5 years, including treatment and follow-up periods.
CONDITIONS
Brief Title
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Research Team
C
Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here